US4436745A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of inhibiting aldose reductase activity
Assignee: Alcon Research LLC
•
Filing: 1982-04-15
•
Granted: 1984-03-13
•
Expires: 2002-04-15
Abstract
Abstract Inhibition of aldose reductase activity with tetracyclic spiro-hydantoins.
Inventors
- 👤 Billie M. York, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 19:05
CPC Classifications
C; C07; C07D; C07D235/00; C07D235/02
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
81 words
A method for treating diabetic complications in mammals comprising administering an effective amount of spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione or pharmaceutically acceptable salt thereof having the formula ##STR24## where x=H, F, Cl, Br, I, SCH 3 , S(O)CH 3 , S(O 2 )CH 3 , OCH 3 and CH 3 , y=H, F, Cl, Br, I, SCH 3 , S(O)CH 3 , S(O 2 )CH 3 , OCH 3 and CH 3 , and z=H, F, Cl, Br, I, OCH 3 and CH 3 .
Claim 2
Independent Claim
81 words
A method for treating diabetic complications in mammals comprising administering an effective amount of spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione or pharmaceutically acceptable salt thereof having the formula ##STR24## where x=H, F, Cl, Br, I, SCH 3 , S(O)CH 3 , S(O 2 )CH 3 , OCH 3 and CH 3 , y=H, F, Cl, Br, I, SCH 3 , S(O)CH 3 , S(O 2 )CH 3 , OCH 3 and CH 3 , and z=H, F, Cl, Br, I, OCH 3 and CH 3 .
Claim 3
Dependent Claim
13 words
A method as recited in claim 1 wherein said complication is diabetic cataract.
Claim 4
Dependent Claim
12 words
A method as recited in claim 1 wherein said complication is neuropathy.
Claim 5
Dependent Claim
12 words
A method as recited in claim 1 wherein said complication is retinopathy.
Claim 6
Dependent Claim
12 words
A method as recited in claim 1 wherein said complication is nephropathy.
Claim 7
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR25##
Claim 8
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula. ##STR26##
Claim 9
Independent Claim
18 words
A method in accordance with claims 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR27##
Claim 10
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR28##
Claim 11
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR29##
Claim 12
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR30##
Claim 13
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR31##
Claim 14
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR32##
Claim 15
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR33##
Claim 16
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR34##
Claim 17
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR35##
Claim 18
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR36##
Claim 19
Independent Claim
19 words
A method in accordance with claims 1, 2, 3, 4 or 5 wherein said spiro-(fluoren-9,4'-imidazolidine)-2',5'-dione has the formula ##STR37##
References Cited (Backward Citations)
US2716648A
Cited
US2683718A
Cited
US3349124A
Cited
DE1135915B
Cited
US3532744A
Cited
US3821383A
Cited
US4117230A
Cited
US4209630A
Cited
US4147795A
Cited
US4130714A
Cited
US4127665A
Cited
US4147797A
Cited
US4200642A
Cited
US4181728A
Cited
US4327107A
Cited
US4181729A
Cited
US4307108A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-03-13 | 1987-09-12 | 1988-03-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-03-13 | 1991-09-12 | 1992-03-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-03-13 | 1995-09-12 | 1996-03-13 | $7700.00 | Window Closed / Lapsed |